MFDS — authorised 28 March 2017
- Marketing authorisation holder: REGENERON PHARMACEUTICALS
- Status: likely_approved
🇰🇷 Dupixent in South Korea
MFDS authorised Dupixent on 28 March 2017
Marketing authorisation
Dupixent in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in South Korea
Frequently asked questions
Is Dupixent approved in South Korea?
Yes. MFDS authorised it on 28 March 2017.
Who is the marketing authorisation holder for Dupixent in South Korea?
REGENERON PHARMACEUTICALS holds the South Korean marketing authorisation.